Subtopic Deep Dive
ALK Mutations in Neuroblastoma
Research Guide
What is ALK Mutations in Neuroblastoma?
ALK mutations in neuroblastoma are activating oncogenic alterations in the ALK kinase receptor gene that drive tumor development and serve as targets for precision therapies like ALK inhibitors.
Activating ALK mutations occur in 6-10% of sporadic neuroblastoma cases and higher frequencies in familial forms. Multiple studies from 2008 identified key mutations such as F1174L and R1275Q (Mossé et al., 2008; Chen et al., 2008; Janoueix-Lerosey et al., 2008). Over 20 papers in the provided list detail their prevalence, genetic landscape, and therapeutic implications, with foundational works garnering 5000+ total citations.
Why It Matters
ALK mutations enable targeted therapies with inhibitors like lorlatinib in relapsed neuroblastoma, improving outcomes in high-risk patients unresponsive to standard chemotherapy (George et al., 2008). Preclinical models confirm mutation-specific sensitivity, guiding clinical trials for precision medicine (Pugh et al., 2013). In high-risk cases with chromothripsis or MYCN amplification, ALK alterations identify actionable drivers, reducing reliance on toxic multi-agent regimens (Molenaar et al., 2012; Matthay et al., 2016).
Key Research Challenges
Mutation Heterogeneity
ALK mutations vary across sporadic (F1174L) and germline (R1275Q) cases, complicating universal inhibitor efficacy (Chen et al., 2008; Janoueix-Lerosey et al., 2008). Secondary resistance emerges via kinase domain alterations in relapsed tumors (Pugh et al., 2013).
Blood-Brain Barrier Penetration
Many ALK inhibitors fail to cross the blood-brain barrier, limiting efficacy in metastatic neuroblastoma (George et al., 2008). Lorlatinib shows promise but requires validation in pediatric trials (Matthay et al., 2016).
Combination Therapy Optimization
ALK inhibitors synergize with MYCN-targeted agents but optimal dosing remains unclear in co-mutated tumors (Huang and Weiss, 2013). Clinical translation lags behind preclinical data (Molenaar et al., 2012).
Essential Papers
Identification of ALK as a major familial neuroblastoma predisposition gene
Yaël P. Mossé, Marci Laudenslager, Luca Longo et al. · 2008 · Nature · 1.4K citations
Neuroblastoma
Katherine K. Matthay, John M. Maris, Gudrun Schleiermacher et al. · 2016 · Nature Reviews Disease Primers · 1.3K citations
Methods in molecular biology
Philippe Métézeau · 1998 · Research in Microbiology · 1.3K citations
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh, Olena Morozova, Edward F. Attiyeh et al. · 2013 · Nature Genetics · 1.2K citations
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen, Junko Takita, Young Lim Choi et al. · 2008 · Nature · 905 citations
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix‐Lerosey, Delphine Lequin, Laurence Brugières et al. · 2008 · Nature · 887 citations
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George, Takaomi Sanda, Megan Hanna et al. · 2008 · Nature · 882 citations
Reading Guide
Foundational Papers
Start with Mossé et al. (2008) for familial ALK discovery (1392 citations), then Chen/Janoueix-Lerosey/George triptych (2008, ~2700 combined citations) for somatic mutations and targeting rationale; Pugh et al. (2013) maps full genetic landscape.
Recent Advances
Matthay et al. (2016, 1334 citations) reviews clinical context; Molenaar et al. (2012, 868 citations) links to chromothripsis; Peifer et al. (2015, 576 citations) covers telomerase rearrangements co-occurring with ALK.
Core Methods
Next-generation sequencing for mutation detection (Pugh et al., 2013); kinase activity assays and Ba/F3 transformation for functional validation (George et al., 2008); patient-derived xenografts and inhibitor dose-response curves (Chen et al., 2008).
How PapersFlow Helps You Research ALK Mutations in Neuroblastoma
Discover & Search
Research Agent uses searchPapers('ALK mutations neuroblastoma F1174L R1275Q') to retrieve 20+ core papers like Mossé et al. (2008, 1392 citations), then citationGraph to map influence from foundational 2008 Nature papers to Pugh et al. (2013). findSimilarPapers on Chen et al. (2008) uncovers parallel discoveries by Janoueix-Lerosey et al. (2008); exaSearch drills into lorlatinib trials absent from abstracts.
Analyze & Verify
Analysis Agent applies readPaperContent on George et al. (2008) to extract mutation-specific IC50 data for inhibitors, then runPythonAnalysis to plot sensitivity curves across F1174L vs R1275Q using pandas. verifyResponse with CoVe cross-checks claims against Matthay et al. (2016), achieving GRADE A for prevalence stats; statistical verification confirms 6-10% somatic rate from Pugh et al. (2013).
Synthesize & Write
Synthesis Agent detects gaps like lorlatinib resistance mechanisms missing post-2016, flags contradictions between preclinical vs clinical responses (Molenaar et al., 2012). Writing Agent uses latexEditText for review drafts, latexSyncCitations to integrate 15 ALK papers, and latexCompile for camera-ready output; exportMermaid generates kinase signaling pathway diagrams from mutation data.
Use Cases
"Analyze ALK inhibitor IC50 data from 2008-2013 neuroblastoma papers using Python."
Research Agent → searchPapers('ALK neuroblastoma inhibitor sensitivity') → Analysis Agent → readPaperContent(George et al. 2008) → runPythonAnalysis(pandas plot F1174L vs R1275Q IC50) → matplotlib figure of dose-response curves.
"Write LaTeX review section on ALK mutations prevalence with citations."
Research Agent → citationGraph(Mossé et al. 2008) → Synthesis Agent → gap detection → Writing Agent → latexEditText('ALK mutations 6-10% sporadic') → latexSyncCitations(Chen/Janoueix-Lerosey 2008) → latexCompile → PDF section.
"Find GitHub repos with ALK neuroblastoma models from key papers."
Research Agent → searchPapers('ALK neuroblastoma preclinical models') → Code Discovery → paperExtractUrls(Pugh et al. 2013) → paperFindGithubRepo → githubRepoInspect → cell line mutation simulator code.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(ALK neuroblastoma 2008-2016) → 50+ papers → DeepScan(7-step: extract mutations → verify prevalence CoVe → Python stats) → structured report with GRADE scores. Theorizer generates hypotheses like 'F1174L resistance via MYCN crosstalk' from Molenaar/Peifer papers. Chain-of-Verification ensures no hallucinated inhibitors beyond lorlatinib.
Frequently Asked Questions
What defines ALK mutations in neuroblastoma?
ALK mutations are gain-of-function changes like F1174L (somatic) and R1275Q (germline) in the ALK kinase domain, activating downstream signaling in 6-10% of cases (Mossé et al., 2008; Chen et al., 2008).
What methods detect ALK mutations?
Sequencing identifies somatic/germline variants; functional assays confirm oncogenicity (Pugh et al., 2013). Preclinical studies use patient-derived xenografts for inhibitor testing (George et al., 2008).
What are key papers on ALK in neuroblastoma?
Mossé et al. (2008, 1392 citations) identified familial predisposition; Chen et al. (2008, 905 citations) and Janoueix-Lerosey et al. (2008, 887 citations) detailed oncogenic mutations; George et al. (2008, 882 citations) validated therapeutic targeting.
What open problems exist?
Resistance mechanisms to ALK inhibitors in relapsed cases; blood-brain barrier penetration for CNS metastases; combinatorial strategies with MYCN/ telomerase inhibitors (Huang and Weiss, 2013; Peifer et al., 2015).
Research Neuroblastoma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching ALK Mutations in Neuroblastoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers